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Abstract
Background: Huntington disease (HD) is caused by a polyglutamine expansion of more than 35 units in the
huntingtin protein. This expanded repeat length inversely correlates with the age-at-onset (AAO), however,
additional genetic factors apart from the expanded CAG repeat size are thought to influence the course and the
AAO in HD. Until now, among others, the gene encoding PCG-1a (PPARGC1A) was shown to modify the AAO in
two independent, however small, populations. PGC-1a is involved in the induction of various mechanisms
regulating mitochondrial biogenesis and oxidative stress defence. Furthermore, several studies have linked
impairment of its function and/or its expression to HD pathogenesis. As the identification of distinct modifiers in
association studies is largely dependent on the size of the observed population, we investigated nine different
single nucleotide polymorphisms (SNPs) in PPARGC1A in order to replicate the disease modifying effect in more
than 800 European HD patients and to identify an association with AAO in HD.
Results: Two SNPs, one in the promoter and one in the transcribed region of the gene, showed a significant effect
on the AAO. While the minor allele of SNP rs7665116 (g.38570C), located in the transcribed gene region, was
associated with a delay in disease onset, especially in HD patients with Italian ancestry, the minor allele of SNP
rs2970870 (g.-1437C) in the promoter region leads to an earlier onset of HD in its homozygous state. Additionally,
global testing of haplotype block 2, which covers the main part of the transcribed region of the gene, revealed an
association between block 2 haplotypes and the disease onset.
Conclusion: Therefore, our results indicate opposing modifying influences of two SNPs within one gene on AAO
and support the idea that PGC-1a dysfunction is involved in HD pathology.
Background
Huntington disease (HD) is one of the most common
autosomal-dominantly inherited neurodegenerative disor-
ders characterized by progressive behavioural and cogni-
tive impairments as well as motor disturbances with a
relentlessly fatal course of 15 to 25 years after disease
onset. The genetic defect of HD is caused by the expan-
sion of an unstable CAG repeat in the HD gene resulting
in an elongated polyglutamine tract in the huntingtin pro-
tein [1]. The onset of the disease mainly depends on the
length of the CAG repeat, which is inversely correlated to
the age-at-onset (AAO), and depending on the examined
population, up to 73% of the variance in the AAO is deter-
mined by the CAG repeat size [2,3]. Similar to other neu-
rodegenerative diseases, the disease causing gene alone
does not fully determine the AAO and the course of the
disease. The rest of the variance in the AAO, which is not
accounted for by the mutant gene, is determined by other
disease-modifying factors and seems to be strongly herita-
ble [4]. To date, several genetic modifiers, particularly for
the AAO of HD have been identified. They include the
genes encoding the huntingtin-associated protein-1
(HAP1) [5], the adenosinergic A2A receptor (ADORA2A)
[6,7], ubiquitin C-terminal hydrolase 1 (UCHL1) [8,9] or
autophagy-related protein 7 (Atg7) [10]. The functions of
the respective gene products are related to various
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Another genetic modifier, recently identified by two
independent association studies, is PPARGC1A: the gene
encoding the peroxisome proliferator-activated receptor
g coactivator 1a (PGC-1a) [11,12]. PGC-1a, initially dis-
covered as a key regulator of adaptive thermogenesis
[13], additionally induces the transcription of cellular
mechanisms regulating respiration and mitochondrial
biogenesis as well as oxidative stress defence [14,15]. In
HD both mitochondrial dysfunction and oxidative stress
are involved in the pathogenesis of the disease [16,17].
Interestingly, PGC-1a knock-out mice display impaired
mitochondrial function, striatal degeneration and a
hyperkinetic movement disorder, which are features also
observed in HD [18,19]. Furthermore, several studies
revealed that impaired PGC-1a function and/or expres-
sion can be found in striatal cell lines, transgenic mouse
models of HD and in post-mortem brain tissue from
HD patients due to interference with mutant huntingtin
[20-22]. Lack of PGC-1a expression even aggravates the
phenotype of transgenic HD mice, whereas PGC-1a
overexpression can rescue some aspects of the striatal
pathology [21]. Therefore, an association between PGC-
1a function and HD pathogenesis seems to be beyond
controversy.
Last year, first Weydt and colleagues [12] and later
Taherzadeh-Fard et al. [11] connected PGC-1a with the
AAO of HD. They identified different polymorphisms to
be associated with the AAO in two cohorts of HD
patients (around 400 patients each). As PPARGC1A is
located on chromosome 4p15.1-2, it is also localized near
a potential modifier region [23,24]. Overall, the two
modifier studies mentioned above examined a large set of
single nucleotide polymorphisms (SNPs) in PPARGC1A,
but not all the SNPs selected were included in both stu-
dies. Therefore, the aim of the present study was to repli-
cate the association of PGC-1a with the AAO of HD in a
large group of more than 800 European HD patients.
Results
In addition to the pathogenic CAG repeat expansion in
the HD gene, other genetic factors play a significant role
in determining AAO in HD. In our present study with a
cohort of 854 European HD patients, the length of the
expanded CAG repeat significantly accounts for
approximately 51% of the variance in the AAO (R2 =
0.5128, P ≤ 0.0001; Table 1), therefore the residual var-
iance of disease onset has to be influenced by additional
factors. In order to identify further genetic modifiers, we
examined nine different SNPs in the gene encoding
PGC-1a. With the exception of one SNP (rs6821591),
all the others were confirmed to be polymorphic with a
frequency of ≥1% in 60 healthy controls (CEPH) and
were thus examined in the HD patients with regard to a
possible effect on the AAO (Figure 1).
An effect of the respective PGC-1a polymorphisms on
the AAO of the examined HD patients was calculated by
applying an analysis of covariance together with the influ-
ence of the expanded HD allele. In this first analysis
rs7665116, which is located at the 3’-end of a highly con-
served region in intron 2, displayed a significant effect on
the HD AAO both in an additive (P = 0.0172; Table 1)
and a dominant model (P = 0.0045; Table 1). A more
detailed analysis of rs7665116 revealed that its associa-
tion with the AAO is primarily observed in HD patients
with Italian ancestry. In this group of a total of 312
patients, rs7665116 significantly affects the onset of their
first symptoms (additive model: P = 0.0172; dominant
model: P = 0.0045; Table 2) and constitutes ~2.4% of the
variance in the AAO. As the expanded CAG repeat in
the HD gene explains 44.4% of the AAO in the Italian
patient group (R2 = 0.4444; Table 2), the SNP represents
~4.3% of the variance that can not be accounted for by
the expanded CAG repeat. The minor allele g.38570C
leads to a delayed disease onset of about three (T/C gen-
otype) to five (C/C genotype) years (Table 3). Although
statistically not significant, the tendency of an increase in
the AAO could clearly be observed.
Apart from rs7665116 in the transcribed region of the
PGC-1a gene, SNP rs2970870, located in the promoter
region, showed a marginally significant effect on the HD
AAO in the first analysis of covariance (P = 0.0566;
Table 1). Under closer scrutiny, rs2970870 revealed a
significant effect on the AAO of HD in patients with
≤55 CAG repeats in an additive statistical model (p =
0.0435; Table 4). As the variability of the AAO is much
higher in patients with CAG repeats less than 55 units,
the CAG repeat in the HD gene only determines about
38% of this variability (R2 = 0.3807; Table 4). Almost 1%
Table 1 Analysis of covariance of PGC1a single
nucleotide polymorphisms
Model Localization R2 ΔR2 P value
HD CAG 0.5128 < 0.0001*
HD CAG + PGC-1a
rs2970865 promoter region 0.5124 -0.0004 0.6436
rs17576121 promoter region 0.5187 0.0059 0.0795
rs2970870 promoter region 0.5180 0.0052 0.0566
rs7665116 intron 2
1-1 vs 1-2 vs 2-2 0.5257 0.0129 0.0389*
1-1 vs 1-2 + 2-2 0.5256 0.0128 0.0112*
rs2970848 intron 7 0.5150 0.0022 0.1355
rs2970847 exon 8 0.5256 0.0128 0.0947
rs8192678 exon 8 0.5060 -0.0068 0.9863
rs3755863 exon 8 0.5063 -0.0065 0.0953
The level of significance was set to P = 0.05; n = 854
HD CAG expanded CAG allele in huntingtin
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of the variance in the AAO of HD can be attributed to
the effect of rs2970870. In the examined group, patients
homozygous for the minor allele g.-1437C developed
their first symptoms on average at the age of 43.7 years,
which is about four years earlier than that of patients
with other genotypes (Table 5).
Several studies previously identified two haplotype
blocks within the PGC-1a gene [12,25,26]. SNP
rs2970870 is located in haplotype block 1, which com-
prises the promoter region of the gene, while rs7665116
is localized in haplotype block 2, covering the main part
of the transcribed region. In our patients group, we
identified a total of seven haplotypes with frequencies
>0.01 in haplotype block 2. While no associations were
found between haplotype block and the AAO of HD,
global testing suggested an association between block 2
haplotypes and the disease onset (Table 6). Particularly,
haplotype-specific statistic scores were highest and low-
est for haplotypes 2-1-1-1-1 and 1-1-1-1-2, respectively.
Although the choice of the examined haplotype block 2
SNPs in this study did not coincide totally with a pre-
vious study by Weydt et al. [12], the specificity and the
association with HD AAO of the different haplotypes
are comparable.
Figure 1 Polymorphic sites and haplotype blocks in PPARGC1A. Linear map with exons (full boxes) and SNP positions relative to the
translational start site. Only rs8192678 results in an amino acid change (G482S). MAF indicates minor allele frequency; SNP qualifiers refer to
database entries http://www.ncbi.nlm.nih.gov/SNP/. Allele and genotype frequencies of rs7665116 (P = 0.0496) and rs2970870 (P = 0.0012) in HD
patients differ significantly from the respective frequencies measured in 60 healthy controls. The localisation of the two haplotype blocks is
shown at the bottom. Scales differ for the transcribed sequence and the 5’-untranscribed promoter sequence.
Table 2 Analysis of covariance of PGC1a rs7665116 in
Italian HD patients
Model R2 ΔR2 P value
HD CAG 0.4444 < 0.0001*
HD CAG + PGC1a rs7665116
1-1 vs 1-2 vs 2-2 0.4682 0.0238 0.0172*
1-1 vs 1-2 + 2-2 0.4681 0.0237 0.0045*
The level of significance was set to P = 0.05; n = 312
HD CAG expanded CAG allele in huntingtin
Table 3 Mean ages-at-onset of the different rs7665116







T/T 210 45.4 (0.33) 46.58 (0.96)
T/C 97 45.6 (0.45) 49.55 (1.43)
C/C 5 44.6 (0.98) 51.80 (2.25)
CAGexp, expanded CAG repeat number; SE, standard error; T, major allele
g.38570T; C, minor allele g.38570C.
an = 312.
t-test: Mean ages-at-onset do not differ significantly between the three
genotypes (T/T vs T/C: P = 0.0570; T/T vs C/C: P = 0.4079; T/C vs C/C:
P = 0.7596).
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Discussion
Genetic association studies provide the possibility to
identify genetic factors that modify a disease apart from
the causative gene. However, some critical aspects
should be considered in association studies. A disease-
associated polymorphism might have varying effects in
different populations and the size of an examined
patient cohort has to be large enough to detect a real
association. Additionally, all studies require the replica-
tion of an identified association in another collective of
patients. Until now, several studies succeeded in identi-
fying various genetic modifiers for HD, which are
involved in the different pathways that contribute to the
pathogenesis of HD.
Here, we replicated the association of common var-
iants in the PPARGC1A gene with the AAO of HD and
can confirm a modifying effect in more than 800 Eur-
opean HD patients. Specifically, two polymorphisms
showed a significant effect on the AAO. SNP rs7665116,
located in the transcribed region of the gene, is asso-
ciated with a delay in disease onset particularly in Italian
HD patients and accounts for ~4.3% of the variance in
the HD AAO that cannot be explained by the CAG
repeat in the HD gene. This result is in agreement with
findings reported by Weydt and colleagues [12], who
also found this effect in HD patients of Italian descent.
The second polymorphism rs2970870, located in the
promoter region of PPARGC1A, modifies the AAO in
patients with ≤55 CAG repeats in the mutated HD gene
and determines almost 1% of the variance in the AAO.
Due to the higher variability of AAO in HD patients
with less than 55 CAG repeats and who have a disease
onset in adulthood this facilitates the detection of other
factors apart from the expanded CAG repeat and there-
fore especially small modifying effects can be more
easily detected in this cohort. While we could replicate
a modifying effect of the polymorphism rs7665116, the
influence of rs2970870 was not described yet in previous
studies [2,11,12].
Recent studies show that PGC-1a, which induces the
expression of genes involved in mitochondrial energy
metabolism in almost every cell type and tissue with
high energy oxidative capacity, could be implicated in
common disease states such as diabetes or heart failure
[26-28]. Several findings also point though, to its invol-
vement in the pathogenesis of neurodegenerative dis-
eases such as HD. Mutant huntingtin was found to lead
to an inhibition of the PGC-1a system in cell and
mouse models of HD as well as in post-mortem brains
of HD patients [20-22]. Although PGC-1a is expressed
in the brain and is associated with neurodegeneration
through mitochondrial impairment, nothing is known
about its exact transcriptional regulation there. At this
time, several findings lead to two hypotheses how
mutant huntingtin interferes with PGC-1a function. On
the one hand, mutant huntingtin may interfere with the
transcription of PGC-1a reducing its expression
[20,21,29]. On the other hand, mutant huntingtin may
bind directly to PGC-1a impairing its ability to regulate
the expression of its downstream target genes [22]. The
first hypothesis is supported by the observation of
Cui at al. [21] that mutant huntingtin represses
CRE-mediated PGC-1a expression in striatal cells by
interfering with the formation of the CREB/TAF4 com-
plex critical for PGC-1a expression. Mutant, but not
wild type huntingtin is associated with the endogenous
PGC-1a promoter suggesting that mutant huntingtin
disrupts the function of promoter bound transcription
factors. Additionally, reduced expression of PGC-1a and
Table 4 Analysis of covariance of PGC1a rs2970870 in
HD patients with ≤ 55 CAGs
Model R2 ΔR2 P value
HD CAG 0.3807 < 0.0001*
HD CAG + PGC1a rs2970870
1-1 vs 1-2 vs 2-2 0.3857 0.0050 0.0435*
1-1 vs 1-2 + 2-2 0.3808 0.0001 0.7566
The level of significance was set to P = 0.05; n = 784
HD CAG expanded CAG allele in huntingtin
Table 5 Mean ages-at-onset of the different rs2970870







T/T 262 44.9 (0.21) 46.37 (0.77)
T/C 404 44.5 (0.15) 48.19 (0.62)
C/C 118 45.4 (0.33) 43.67 (1.15)
CAGexp, expanded CAG repeat number; SE, standard error; T, major allele g.-
1437T; C, minor allele g.-1437C.
an = 784.
bt-test: Patients ≤ 60 CAG repeats and genotype C/C differ significantly from
patients with T/T and T/C genotype (p = 0.0039).
Table 6 Analysis of PGC1a Block 2 Haplotypes on HD
age-at-onset
Haplotype Frequency Score P value
1-1-1-1-2 0.2072 -1.892 0.0585
1-2-1-1-1 0.1550 -1.636 0.1018
1-1-1-2-1 0.1469 -1.218 0.2232
1-1-1-1-1 0.1269 0.749 0.4538
1-1-2-1-1 0.0725 1.125 0.2606
1-1-1-2-1 0.0665 1.724 0.0847
2-1-1-1-1 0.0511 2.886 0.0039
n = 729; adjusted for CAG repeat size (CAGlog)
P = 0.0113 for global haplotype statistics; block 2 haplotypes: 1, more
common allele (+38570T, +74774A, +75657C, +75919G, +76059G); 2, less
common allele (+38570C, +74554G, +75657T, +75919A, +76059A)
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its target genes was reported in muscle of HD patients
[20]. In contrast, reduced expression of PGC-1a target
genes, but not PGC-1a itself in brown adipose tissue
argues for the second hypothesis [22]. The results of the
present study support both discussed hypotheses as we
identified a genetic association of the PGC-1a gene both
via its promoter and the transcribed region. The effects
of the two modification sites are oppositional to each
other. The polymorphism rs2970870 in the promoter
region leads to approximately four years earlier onset of
HD. One could speculate that the disruption of a further
transcriptional binding site by the polymorphism results
in an earlier AAO and an intensified course of the dis-
ease. In contrast, haplotype block 2 of PPARGC1A, which
covers the main part of the transcribed region of the
gene, and polymorphism rs7665116, located in the tran-
scribed region, also show an association with HD. Poly-
morphism rs7665116 even is associated with a three to
five years delay in the disease onset and thus seems to
antagonize a dysfunction of the protein.
Although the findings for a failure in PGC-1a expres-
sion predominate, there is also evidence to suggest an
impaired functional ability of the protein itself. However,
the two mechanisms for how mutant huntingtin may
regulate PGC-1a activity are not mutually exclusive as
PGC-1a may induce its own expression via a positive
autoregulatory loop through calcium signalling compo-
nents [30,31]. Additionally, the respective pathway regu-
lating and determining the loss of PGC-1a function may
depend on the tissue type, the amount of soluble and/or
aggregated mutant huntingtin in the cell, and possibly
the stage of disease. Even though expressed ubiqui-
tously, the expression level of huntingtin varies in the
different tissues and shows its highest level in brain
[32,33]. It is therefore conceivable that the pathway
influencing PGC-1a function may be dependent on the
amount of mutant huntingtin in the respective tissue.
This is closely connected to the general amount of solu-
ble and aggregated huntingtin in the cell. Huntingtin
not only is associated with PGC-1a, but also with a
number of other transcription factors including CREB
binding protein, SP1 or p53 [34-36], which are seques-
tered in huntingtin aggregates and thus repressing the
transcription of their respective target genes. In order to
understand and answer the question about the exact
regulative pathway, further functional analyses of PGC-
1a and its interacting and associated proteins are
needed. Finally, all these pathways lead to mitochondrial
dysfunction, abnormalities in energy metabolism and
cell death providing a link to other neurodegenerative
diseases such as Alzheimer or Parkinson disease.
In conclusion, the findings presented here support the
association of PGC-1a with HD pathogenesis and thus
mitochondrial impairment, especially in humans. As the
exact mechanism of PGC-1a regulation and its interfer-
ence with mutated huntingtin is unsolved and discussed
contrarily, our observations provide an informative basis
for both existing concepts. A modifier in the promoter
region of PPARGC1A, encoding PGC-1a, may influence
a failure in PGC-1a expression. A modification site in
the transcribed region of the gene on the other hand
may affect an impaired PGC-1a function towards target
genes. As both regulative pathways seem to lead to
mitochondrial dysfunction, the identification of the two
modification sites in PGC-1a offers the possibility to
further elucidate the role of PGC-1a in HD pathogen-
esis and for its future use as a therapeutic target.
Methods
HD patients
In total, we examined 854 unrelated European HD
patients [5,10,37]. Of these, 352 patients were of German,
322 patients of Italian descent. The remaining 180
patients were from other European countries. For all
patients, HD was clinically diagnosed and AAO was esti-
mated as the age at which motor and/or cognitive symp-
toms first occurred. The mean AAO of HD patients was
45.9 (SD 13.4) and ranged from 5 to 85 years. CAG
repeat lengths in the HD gene had been tested in all
patients and CAG numbers have been standardized in a
reference laboratory. The number of the expanded CAG
repeats ranged from 39 to 90 with a median repeat num-
ber of 44. All participating individuals gave informed
consent according to the Declaration of Helsinki.
Genotyping
To detect potential modifying effects of the PGC-1a
gene on AAO in HD we selected nine single nucleotide
polymorphisms (SNPs), which are located in two distinct
haplotype blocks [12,25,26]. Three SNPs in haplotype
block 1 at gene positions -3974 T > C (rs2970865),
-1694 T > C (rs17576121), and -1437 T > C
(rs2970870), and six SNPs in haplotype block 2 at gene
positions 38570 T > C (rs7665116), 74554 A > G
(rs2970848), 75657 C > T (rs2970847), 75919 G > A
(rs8192678), 76059 G > A (rs3755863), and 94581 C >
T (rs6821591) were analysed in more than 800 HD
patients as well as in 60 healthy controls (CEPH) (Figure
1). The single SNPs were particularly selected from
dbSNP http://www.ncbi.nlm.nih.gov/snp/ and are con-
sistent with SNPs analysed in two previous association
studies by Taherzadeh-Fard et al. [11] and Weydt et al.
[12]. In order to validate the achieved results in an addi-
tional HD patient cohort, our study included only those
SNPs examined by both studies and those that were
identified with a significant impact on the AAO of HD
in at least one of the studies. Among variant sites,
rs8192678 results in an amino acid change (Gly > Ser).
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Genotyping of the SNPs rs2970865, rs17576121,
rs2970870, rs7665116, rs2970848, rs3755863, and
rs6821591 was performed by a high resolution melting-
based PCR using LightCycler® 480 High Resolution Mas-
ter (Roche Diagnostics, Mannheim) carried out on the
LightCycler® 480 (Roche Diagnostics, Mannheim) follow-
ing manufacturer’s instructions. In order to facilitate dif-
ferentiation of homozygous samples (homozygous for the
major allele - homozygous for the rare allele) we used a
pooling method described by Michael Liew et al. [38]
that reveals the possibility to genotype homozygote sam-
ples by adding a known sample with a homozygous geno-
type to an unknown sample before amplification.
Genotyping of the SNPs rs8192678 and rs2970847 was
performed by standard PCR conditions and a following
restriction analysis using specific enzymes. The respec-
tive PCR products were incubated with 4U MspI
(rs8192678) and 1U BsaWI (rs2970847) according to the
manufacturer’s instructions (New England Biolabs, Inc.,
Beverly, MA, USA).
Single correct typing results as well as ambiguous
results were verified and controlled by sequencing with
CEQ 8000 Dye Terminator Cycler Sequencing (Beck-
man Coulter Inc., USA) according to manufacturer’s
instructions.
To verify a frequency of ≥ 1% of the SNPs in healthy
controls, we first analysed the respective SNPs in 60
control samples (CEPH). Having identified a polymorph-
ism with ≥ 1% frequency, we determined the respective
SNPs in the HD patients. Showing a frequency <1% in
healthy controls, SNP rs6821591 was not further ana-
lysed in the patients group.
Statistical analysis
Allele and genotype frequencies as well as Hardy-Wein-
berg distribution of the examined genotypes were investi-
gated by Genepop version 4.0.10 http://genepop.curtin.
edu.au/. Using the framework of linear models in an analy-
sis of variance and covariance (JMP® Version 7.0.1 SAS
institute, Inc., Cory, NC, USA) we tested the modifying
role of the different PGC-1a SNPs on the AAO of HD.
First, we applied a model of analysis of covariance with the
respective SNPs and the expanded HD allele as indepen-
dent variables and the AAO as a dependent variable. The
goodness-of-fit was evaluated by the proportion of varia-
tion in the AAO explained by the coefficient of determina-
tion (R2). We obtained the best fit of our data and a
minimization of the residuals by logarithmic transforma-
tion of the AAO and the CAG repeat number in HD. To
determine the effect of the polymorphisms on AAO by an
analysis of variance and covariance, the effect of the
expanded HD allele (HD CAG) was calculated alone, as
well as with different SNPs. When the respective factors
were added to the effect of the expanded HD allele (ΔR2),
a change of R2 indicated a relative improvement of the
model. This method identified the percentage of the var-
iance that was attributable to the candidate modifier loci
when there was a significant P-value (P ≤ 0.05). Patients
that could not be genotyped for single SNPs were
excluded from statistical analyses. Differences in the AAO
of HD within different genotypes of the analyzed poly-
morphisms were determined by a two-tailed t-test (JMP®
Version 7.0.1, SAS institute, Inc., Cory, NC, USA). In
order to test associations between haplotypes and AAO,
we used the haplo.stats software 1.4.4 http://mayoresearch.
mayo.edu/mayo/research/schaid_lab/software.cfm.
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